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Maribavir (MBV) inhibits Epstein-Barr virus (EBV) replication and the enzymatic activity of the viral protein kinase BGLF4.
MBV also inhibits expression of multiple EBV transcripts during EBV lytic infection. Here we demonstrate, with the use of a
BGLF4 knockout virus, that effects of MBV on transcription take place primarily through inhibition of BGLF4. MBV inhibits
viral genome copy numbers and infectivity to levels similar to and exceeding levels produced by BGLF4 knockout virus.
Although a number of antiviral drugs are effective inhibitors ofEpstein-Barr virus (EBV) replication and are used empiri-
cally, none is of proven effectiveness for treatment of EBV infec-
tion (1, 2). Maribavir (MBV), which is in late-stage clinical trials
for use against human cytomegalovirus (HCMV) infection in al-
logeneic stem cell and bone-marrow transplant recipients (3, 4), is
of special interest because it is also a potent inhibitor of EBV
replication (5–7). In stem-cell and organ transplant recipients,
EBV infection poses the hazard of generating B-cell lymphomas
that are ultimately fatal. While no drugs are currently approved
for treatment of EBV disease, several that inhibit EBV are avail-
able, and these can be divided into two main classes: those that
target the viral DNA polymerase and those that function indepen-
dently of it (8–12). Acyclic nucleoside and phosphonated nucleo-
tide analogs, as well as pyrophosphate analogs, all target the viral
polymerase.
A new class of HCMV inhibitors, benzimidazole compounds,
with more specific antiviral properties and fewer adverse side effects,
blocked HCMV DNA maturation and encapsidation processes and
led to the design of 1-H--L-ribofuranoside-2-isopropylamino-5,6-
dichlorobenzimidazole (maribavir [MBV]) (13–20). Unlike its par-
ent compound, which inhibits HCMV replication but not EBV rep-
lication, MBV inhibits both (7, 21). Inhibitory effects of MBV are
produced mainly through inhibition of the HCMV and EBV protein
kinases (PK) (21–24). Previous phase 3 studies with a dosage of 100
mg twice a day (BID) did not have sufficient activity to prevent
HCMV disease, but the safety profile and data from case studies sug-
gested that higher doses would be clinically active (3). MBV is now in
new phase 2 trials at doses of 400, 800, and 1,200 mg BID (3).
Maribavir selectively inhibits the HCMV protein kinase, UL97,
determined by direct inhibition of kinase activity in vitro and by
genetic mapping of the MBV-resistant phenotype (21). MBV also
inhibits the EBV protein kinase (BGLF4), resulting in inhibition
of phosphorylation of the EBV DNA processivity factor BMRF1,
but does not seem to act directly on the EBV kinase in vitro (7, 24).
We have recently found that MBV also inhibits expression of
multiple EBV transcripts, in contrast to acyclovir (ACV), which
has little effect on EBV RNAs. Thus, MBV has a unique dual effect
on viral DNA transcription as well as replication (25). In this
study, we find that the inhibitory profile of MBV transcripts is
similar to that produced by mutant EBV in which PK expression
and activity have been knocked out (26). Thus, the results suggest
that MBV largely affects EBV transcript levels through inhibition
of BGLF4.
To determine if the profile of viral transcripts produced by
MBV is mediated by the viral kinase, we utilized BGLF4 knockout
(KO) (dBGLF4/NeoST) and revertant (dBGLF4/NeoSt/R) viruses
constructed and characterized by Murata et al. (26). 293 cells
maintaining wild-type (WT), BGLF4 knockout, and revertant
EBV genomes (27) were induced into the lytic cycle by transfect-
ing the EBV immediate early transactivator BZLF1, and lysates
were probed by Western blotting after 48 h. Figure 1A demon-
strates that expression of BGLF4 is abolished in the PK knockout
but not the revertant cell line. Expression of the early EBV ribo-
nucleotide reductase large subunit (RR1), used as a control, was
unaffected in both cell lines. In contrast, phosphorylation of
BMRF1, used as an indicator of BGLF4 activity, was detected only
upon expression of BGLF4 (upper band, BMRF1 panel). Immu-
nofluorescence staining of induced cell lines shows efficient viral
induction as indicated by the detection of BMRF1 (Fig. 1C). These
findings confirm nonexpression of BGLF4 in the knockout virus,
inhibition of phosphorylation of its natural substrate BMRF1, and
efficient induction of the lytic cycle.
To measure the effects of MBV and the PK knockout virus on
EBV transcripts, we profiled EBV mRNA using real-time quanti-
tative PCR (qPCR) as described before (25). Cell viability assays
were performed with MBV concentrations up to 80 M; no evi-
dence of toxicity for the cell lines used was detected below 80 M
MBV (Fig. 1B). Twenty micromolar MBV is used in these studies
as before and was not toxic at the concentration used.
As expected, most EBV mRNAs were maximally induced 48 h
after lytic cycle induction with BZLF1, compared with findings at
24 h (Fig. 2A). WT and revertant (REV) virus showed the same
pattern of gene expression. MBV reduced overall EBV mRNA lev-
els at 48 h, except for immediate early genes, such as BMLF1 (Fig.
2D). The PK KO virus exhibited significantly reduced gene expres-
sion at 48 h compared with findings for WT and revertant viruses.
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We observed two classes composed of late transcripts, i.e., those
genes not detected at 24 h but strongly upregulated at 48 h. Class I
RNAs, such as BALF1, were equally inhibited by either MBV or PK
KO (Fig. 2E). Class II RNAs, although inhibited by MBV com-
pared with results with WT or REV, were even more strongly
inhibited with the PK KO virus alone (Fig. 2B and C). All data were
normalized to the mean for three housekeeping genes, which cor-
related well across all experiments (Fig. 2F). The relative expres-
sion levels (delta cycle threshold [dCT]) were normally distributed
(Fig. 2G), which allowed use of a t test for individual comparisons.
FIG 2 Transcription profiles of EBV mRNAs at 24 and 48 h after induction for different viruses, wild-type (WT), revertant (REV), and PK knockout (PKKO),
in the presence of 20 M maribavir or with mock treatment. (A) Heat map of relative mRNA levels (dCT), color coded: red corresponds to the highest, orange
to the middle, and yellow to the lowest mRNA levels across the experiments. Raw CT values were normalized to geometric means for three cellular mRNAs to yield
dCT values. Genes are listed on the vertical axis and conditions on the horizontal axis. (B to E) Individual transcription profiles representing the main patterns
of changes in mRNA levels. Error bars represent the most conservative estimates of biological variation: twice % standard deviation of dCT for housekeeping
genes (actin, beta actin, and gapdh) measured across n  11 independent biological replicates. (F) Correlation of housekeeping mRNAs to each other and the
geometric means, labeled “house,” of the “ACTIN,” “GAPDH,” and “B-ACT” qPCR assays. Shown are pairwise scatter plots with a fitted linear regression line
(red) on the lower left, univariate CT distribution as a histogram with overlaid kernel density estimate on the diagonal, and pairwise Pearson correlation
coefficient on the upper left. (G) Quantile-quantile plot comparing the distribution of dCT on the vertical to expected values under an assumption of normal
distribution. A histogram is shown on the vertical axis. Also shown is a linear regression fit, which indicates that the data follow a normal distribution and thus
the t test is appropriate for individual comparisons. (H) Distribution of log (lg) q value tests the ability of individual primers to distinguish between experimental
conditions; the q value is a measure of statistical significance adjusted for multiple comparisons using a false discovery rate approach (28). The blue line indicates
q  0.01. (I) Number of significant genes for a given q-value cutoff: 40 genes had q  0.1, as indicated by red shading (corresponding to P  0.05 by single
comparison). (J) Expected number of false-positive genes on the vertical axis given a set of significant genes. We expect 4 false-positive genes in the top 40 genes
that individually discriminate among the experimental conditions: MBV exposure, viral PK status, and time postinduction.
FIG 1 Protein expression in induced PK knockout and revertant cell lines. (A) Viral reactivation in PK/KO and revertant cell lines was induced with EBV BZLF1
for 48 h. Total lysates were immunoblotted with antibodies against BGLF4, RR1, and BMRF1. The faint bands in the BGLF4 panel are likely nonspecific. (B) Cell
viability assays of 293 EBV WT cells. Cells were treated with indicated amounts of MBV for 48 h, and viable cells were counted. Results indicate no loss in viability
with MBV concentrations less than 80 M. (C) Immunofluorescence staining of induced PK knockout and revertant cell lines. Cell lines containing green
fluorescent protein (GFP)-labeled EBV genome are shown in green. BMRF1 staining is visualized in red. BMRF1 is not detected in uninduced samples, but
efficient induction, reflected by BMRF1 expression, is observed at 48 h postinduction and is unaffected by MBV.
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We adjusted for multiple comparisons, since we used multiple
genes, using q-value method (28) (Fig. 2H to J). We interpret these
data to mean that MBV inhibits the kinase activity of PK and thus
the kinase-dependent functions of PK, but there may also be ki-
nase-independent functions of PK, which would not be affected.
In terms of temporal viral mRNA transcription, the PK KO virus is
more inhibited than wild-type virus by treatment with MBV.
Since knockout of BGLF4 had been shown to decrease viral
infectivity 10-fold (26), we next determined whether MBV pro-
duced levels of viral genome copies and infectivity similar to those
produced by knocking out BGLF4. 293EBV WT and PK knock-
out cell lines were induced with BZLF1, and supernatant fluids
were collected at 72 h. Intracellular genome copies were deter-
mined as described before (29). Figure 3A demonstrates that MBV
treatment of WT virus results in a 74% (6.9%) reduction in
genome copy numbers. Compared with results for the WT, induc-
tion of the PK knockout cell line yielded 64% (4.7%) of viral
genome copies. Treatment of PK KO cells with MBV reduced
genome copies by an additional 25% (4.4%). These results dem-
onstrate that the PK KO virus is deficient in making viral genome
copies and suggests that MBV also partially inhibits viral replica-
tion through a mechanism distinct from the viral PK activity.
Supernatant fluids were collected from 293EBV and PK KO
cell lines, and titers of infectious virus were determined by infect-
ing Raji cells (29). MBV resulted in an 82% decrease in viral infec-
tivity—similar to the level observed in untreated PK knockout
virus-infected cells (Fig. 3B). MBV treatment of the PK knockout
line further decreased viral infectivity. This observation suggests
that about half of the PK knockout genome copies are not released
from the cell or are released but noninfectious. This is consistent
with our earlier findings indicating that the viral PK is necessary
for efficient viral egress (29).
These findings demonstrate that MBV can efficiently inhibit
viral transcription (25), genome replication, and infectivity, pro-
ducing pleiotropic effects which are similar to those observed with
viral PK knockout virus. These data are congruent with the func-
tion of MBV working largely but not entirely through inhibition
of BGLF4. MBV likely also inhibits residual infectivity that is still
observed in the absence of PK-mediated effects (Fig. 3B). Con-
versely, transcript levels of the PK KO virus are severely attenuated
compared with those of the wild-type virus. Since BGLF4 has as
many as 20 viral targets (30), MBV may also affect downstream
targets indirectly.
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